Search Results
220 items found for "cancer biology"
- Pharmacological inhibition of neuropeptide Y receptors Y1 and Y5 reduces hypoxic breast cancer migration, proliferation, and signaling
Immunology Pharmacological inhibition of neuropeptide Y receptors Y1 and Y5 reduces hypoxic breast cancer This abundance is exploited for cancer imaging, but there is interest in pharmacological inhibition of the NPYRs to interrogate their functional relevance in breast cancer. Therefore, these antagonists may aid in the development of novel cancer therapeutics and patient-based Tags Breast cancer , GPCR , Hypoxia , NPY , Neuropeptide .
- Simultaneous activation of CXC chemokine receptor 4 and histamine receptor H1 enhances calcium signaling and cancer cell migration
Simultaneous activation of CXC chemokine receptor 4 and histamine receptor H1 enhances calcium signaling and cancer and is involved in several cancer phenotypes including tumor growth, survival, and metastasis. The roles of histamine and histamine receptor H1 (HRH1) in cancer pathogenesis remain controversial. Here, we show that HRH1 is widely expressed in various cancer cell lines and cancer tissues and that coexpression of CXCR4 and HRH1 is associated with poor prognosis in breast cancer.
- Unveiling G-protein coupled receptors as potential targets for ovarian cancer nanomedicines: from RNA sequencing data analysis to in vitro validation
GPCRs in Oncology and Immunology Unveiling G-protein coupled receptors as potential targets for ovarian cancer analysis to in vitro validation Published date July 27, 2024 Abstract "Genetic heterogeneity in ovarian cancer To address the genetic heterogeneity of ovarian cancer, a future personalised approach could include the identification of unique GPCRs expressed in cancer biopsies, matched with personalised GPCR-targeted Subsequently, primary ovarian cancer cells derived from ascites and ovarian cancer cell lines were used
- The power of many: Multilevel targeting of representative chemokine and metabolite GPCRs in personalized cancer therapy
power of many: Multilevel targeting of representative chemokine and metabolite GPCRs in personalized cancer highlights five GPCRs able to orchestrate tumor immunobiology at three main levels: tumor immunity, cancer Authors Donato Inverso, Carlotta Tacconi, Serena Ranucci, Marco De Giovanni Tags Angiogenesis , Cancer
- [1,2,4]Triazolo[1,5-c]pyrimidines as Tools to Investigate A3 Adenosine Receptors in Cancer Cell Lines
and Immunology [1,2,4]Triazolo[1,5-c]pyrimidines as Tools to Investigate A3 Adenosine Receptors in Cancer 7, 2023 Abstract "A3 adenosine receptor is an interesting target that showed controversial roles in cancer Compound 20 has been tested on both A3 adenosine receptor positive cancer cell lines (CHO-A3AR transfected , THP1 and HCCT26) and in A3 negative cancer cell lines, showing no effect on the latter and a proliferative Karl-Norbert Klotz , Sabrina Pacor , Stefano Moro , Giampiero Spalluto Tags A3 adenosine receptor , Cancer
- Vasoactive intestinal peptide receptor 2 signaling promotes breast cancer cell proliferation by enhancing the ERK pathway
GPCRs in Oncology and Immunology Vasoactive intestinal peptide receptor 2 signaling promotes breast cancer Increased VIPR2 mRNA expression and/or VIPR2 gene copy number has been documented in several cancers However, the pathophysiological role of increased VIPR2 in the proliferation of breast cancer cells remains In this study, we found that VIPR2 overexpression in MCF-7 and MDA-MB-231 cells, human breast cancer Increased VIPR2 also exacerbated intraperitoneal proliferation of breast cancer MDA-MB-231 cells in a
- PAXIP1-AS1 is associated with immune infiltration and predicts poor prognosis in ovarian cancer
Immunology PAXIP1-AS1 is associated with immune infiltration and predicts poor prognosis in ovarian cancer antisense RNA 1 (PAXIP1-AS1) was found to promote proliferation, migration, EMT, and apoptosis of ovarian cancer infiltration of OC patients and its regulatory network are unclear. 379 OC tissues were collected from The Cancer
- Session II | Adhesion GPCR Workshop 2024 | Dr. GPCR Ecosystem
Stephen, Caron Kathleen M Department of Cell Biology and Physiology at UNC Chapel Hill 111 Mason Farm Van Meir’s research examines how genetic alterations and hypoxia induce changes in cell biology that : Department of Biology, Ashoka University. Currently: University of Leipzig Mansi Tiwari: Department of Biology, Ashoka University. I joined the Department of Biology at Ashoka University in 2020 as an assistant professor."
- The GPCR-Gαs-PKA signaling axis promotes T cell dysfunction and cancer immunotherapy failure
< GPCRs in Oncology and Immunology The GPCR-Gαs-PKA signaling axis promotes T cell dysfunction and cancer June 12, 2023 Abstract "Immune checkpoint blockade (ICB) targeting PD-1 and CTLA-4 has revolutionized cancer However, many cancers do not respond to ICB, prompting the search for additional strategies to achieve we cross-integrated large singe-cell RNA-sequencing datasets from CD8+ T cells covering 19 distinct cancer
- Session VIII | Adhesion GPCR Workshop 2024 | Dr. GPCR Ecosystem
Institute for Diabetes and Cancer, Helmholtz Centre Munich, Germany, 2. Centre for Experimental Medicine, Institute for Biocehmistry and Molecular Cell Biology, University Medical Centre, Munich 2015 - 2018 Postdoctoral fellow, Department of Adipose Tissue Biology, Institute for Diabetes and Cancer, Helmholtz Diabetes Centre, Munich 2012 - 2015 Postdoctoral fellow, Department of Cell and Molecular Biology, Karolinska Institute, Sweden" Anastasia Georgiadi on the web Endocrine Pharmacology
- Functional Assessment of Cancer-Linked Mutations in Sensitive Regions of Regulators of G Protein Signaling Predicted by Three-Dimensional Missense Tolerance Ratio Analysis
< GPCR News < GPCRs in Oncology and Immunology Functional Assessment of Cancer-Linked Mutations in Sensitive Genetic variants in RGS proteins are associated with many diseases, including cancers, although the impact Intolerant and tolerant-control residues that overlap with pathogenic cancer mutations reported in the COSMIC cancer database were selected to define the functional phenotype. Identified intolerant residues with reported cancer-linked mutations RGS14-R173C/H and RGS4-K125Q/E126K
- Colorectal cancer incidence trends in Golestan, Iran: An age-period-cohort analysis 2004-2018
< GPCR News < GPCRs in Oncology and Immunology Colorectal cancer incidence trends in Golestan, Iran: the effects of factors including age, birth year (cohort) and diagnosis year (period) on colorectal cancer Methods: We obtained data on incidence cases of CRC from the Golestan Population-based Cancer Registry Weiderpass , Gholamreza Roshandel , Freddie Bray , Reza Malekzadeh Tags Age-Period-Cohort model , Colorectal Cancer
- Esophageal and gastric cancer incidence trends in Golestan, Iran: An age-period-cohort analysis 2004 to 2018
< GPCR News < GPCRs in Oncology and Immunology Esophageal and gastric cancer incidence trends in Golestan June 29, 2023 Abstract "Golestan province in the northeast of Iran is part of the Asian esophageal cancer belt and is known as a high-risk area for esophageal (EC) and gastric cancers (GC). on incident cases of EC and GC during 2004 to 2018 were obtained from the Golestan Population-based Cancer
- Ep 52 with Dr. Benjamin Myers
University of Utah School of Medicine in Salt Lake City, UT, and an investigator with the Huntsman Cancer focuses on Smoothened and other class F GPCRs which play essential roles in embryonic development and in cancer these atypical 7-transmembrane receptors, combining biochemical and structural approaches with cell biology Ben studied developmental and cancer signaling as a postdoctoral fellow with Philip Beachy at Stanford
- GPR37 promotes colorectal cancer against ferroptosis by reprogramming lipid metabolism via p38-SCD1 axis
< GPCR News < GPCRs in Oncology and Immunology GPR37 promotes colorectal cancer against ferroptosis by reprogramming lipid metabolism via p38-SCD1 axis Published date September 21, 2024 Abstract "Colorectal cancer Further tests showed that GPR37 protects cancer cells from ferroptosis by upregulating SCD1 expression
- Posters | Adhesion GPCR Workshop 2024 | Dr. GPCR Ecosystem
Hailey Steichen, Krystin Eaton, Teagan Yan, and Nathan Zaidman; Department of Biochemistry and Molecular Biology Jianxiang Xue "I am a postdoctoral researcher working in the Department of Biochemistry and Molecular Biology Department of Biochemistry and Molecular Biology, The University of Chicago, Chicago, IL, USA; 2. Current affiliation: Department of Structural Biology, Genentech, South San Francisco, CA, USA" About Vincent 3, Leduc Richard 4, Olivares-Reyes Jesús Alberto 2, Boucard Antony A1. 1 Department of Cell Biology
- Regulator of G protein signaling 16 restrains apoptosis in colorectal cancer through disrupting TRAF6-TAB2-TAK1-JNK/p38 MAPK signaling
GPCRs in Oncology and Immunology Regulator of G protein signaling 16 restrains apoptosis in colorectal cancer disrupting TRAF6-TAB2-TAK1-JNK/p38 MAPK signaling Published date June 21, 2024 Abstract "Colorectal cancer (CRC) remains a major global cause of cancer-related mortality, lacking effective biomarkers and therapeutic modulators play essential role within regulating downstream signaling of GPCR receptors, with function in cancers
- Identification of a G-protein coupled receptor-related gene signature through bioinformatics analysis to construct a risk model for ovarian cancer prognosis
receptor-related gene signature through bioinformatics analysis to construct a risk model for ovarian cancer prognosis Published date June 18, 2024 Abstract " Background: Ovarian cancer (OV) is a common malignant Method: We downloaded data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases Li, Chunfang Ha Tags G protein-coupled receptor , Immune infiltration , Molecular marker , Ovarian cancer
- NPFF stimulates human ovarian cancer cell invasion by upregulating MMP-9 via ERK1/2 signaling
< GPCR News < GPCRs in Oncology and Immunology NPFF stimulates human ovarian cancer cell invasion by Epithelial ovarian cancer (EOC) is a leading cause of death among gynecological malignancies. Fang , Peter C K Leung , Jung-Chien Cheng Tags Invasion , MMP-9 , NPFFR2 , Neuropeptide FF , Ovarian cancer
- Systems Pharmacodynamic Model of Combination Gemcitabine and Trabectedin in Pancreatic Cancer Cells. Part II: Cell Cycle, DNA Damage Response, and Apoptosis Pathways
and Immunology Systems Pharmacodynamic Model of Combination Gemcitabine and Trabectedin in Pancreatic Cancer prior study, we reported the synergistic cytotoxic effects of gemcitabine and trabectedin on pancreatic cancer analysis was performed, and a system pharmacodynamics model (SPD) was developed to capture pancreatic cancer Straubinger , William J Jusko Tags Systems Pharmacodynamic , drug combination , gemcitabine , pancreatic cancer
- Opposite Effects of Src Family Kinases on YAP and ERK Activation in Pancreatic Cancer Cells: Implications for Targeted Therapy
Oncology and Immunology Opposite Effects of Src Family Kinases on YAP and ERK Activation in Pancreatic Cancer adenocarcinoma (PDAC) remains an aggressive disease that is expected to become the second cause of cancer siRNA-mediated knockdown of YES1, and transfection of epitogue-tagged YAP mutants in PANC-1 and Mia PaCa-2 cancer
- Activation of PI3K/Akt pathway by G protein-coupled receptor 37 promotes resistance to cisplatin-induced apoptosis in non-small cell lung cancer
protein-coupled receptor 37 promotes resistance to cisplatin-induced apoptosis in non-small cell lung cancer Published date September 21, 2023 Abstract "Objectives: Lung cancer is a major public health concern and represents the most common cause of cancer-related death worldwide. protein-coupled receptor 37 (GPR37) exhibits unknown functions in tumors, particularly in non-small-cell lung cancer
- Ep 135 with Dr. Katarzyna Marcinkiewicz
joined in April 2020, following three years on the editorial teams of Nature Structural and Molecular Biology Weill Cornell Graduate School of Medical Sciences in New York City, studying epigenetic changes in cancer Katarzyna handles submissions in structural biology, biophysics and biochemistry, with a particular focus
- Ep 60 with Dr. Josephine (Pina) Cardarelli
The company’s mission is to discover and develop highly effective cancer therapeutics by targeting heteromers Cardarelli is a drug development leader with extensive experience driving drug discovery teams in bringing biologics She has expertise in cell biology, pharmacology, translational medicine, oncology, immuno-oncology, immunology Previously, she held the position of Vice President of Cell Biology & Pharmacology, at Bristol-Myers She has extensive experience working with Biologics, and Antibody Drug Conjugates as well as experience
- Ep 54 with Dr. JoAnn Trejo
control cell signaling by protease-activated receptors (PARs) and the impact on vascular inflammation and cancer Discovering new aspects of PAR signaling is important for increasing the fundamental knowledge of GPCR biology research has focused on PAR1, which has important functions in hemostasis, thrombosis, inflammation, and cancer protease-activated receptors, particularly PAR1, and over the years she has discovered novel aspects of GPCR biology
- G protein-coupled estrogen receptor (GPER)/GPR30 forms a complex with the β1-adrenergic receptor, a membrane-associated guanylate kinase (MAGUK) scaffold protein, and protein kinase A anchoring protein (AKAP) 5 in MCF7 breast cancer cells
guanylate kinase (MAGUK) scaffold protein, and protein kinase A anchoring protein (AKAP) 5 in MCF7 breast cancer β1-adrenergic receptor (β1AR) are G protein-coupled receptors (GPCR) that are implicated in breast cancer MCF7 breast cancer cells express GPR30, β1AR, MAGUKs, and AKAP5 in the plasma membrane, and co-immunoprecipitation Stephen Serafin , Tobias Schmidt , Björn Olde , Kathleen M Caron , L M Fredrik Leeb-Lundberg Tags Breast cancer
- Session III | Adhesion GPCR Workshop 2024 | Dr. GPCR Ecosystem
There, I investigated Two-Pore-Potassium channels using electrophysiology, molecular and chemical biology from discovery to preclinical candidate nomination and to provide the tools to advance adhesion GPCR biology Sabbagh undertook post-doctoral fellowships at the Ontario Cancer Institute and the University of Toronto projects aimed on drug discovery of small molecules for the treatment of inflammatory disorders and cancer Department of Biochemistry and Molecular Medicine, Institute for Research in Immunology and Cancer (IRIC
- Gi/o GPCRs drive the formation of actin-rich tunneling nanotubes in cancer cells via a Gβγ/PKCα/FARP1/Cdc42 axis
GPCRs in Oncology and Immunology Gi/o GPCRs drive the formation of actin-rich tunneling nanotubes in cancer Using a model of human adrenocortical cancer cells, here we established that activation of the GPCR OXER1